rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.14412/1995-4484-2019-218-221rsp-2708Research ArticleОБЗОРЫПроблемы низкой активности и ремиссии при системной красной волчанкеProblems of low activity and remission in systemic lupus erythematosusСоловьевС. К.SolovievS. K.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow, 115522

sksoloviev@mail.ruАсееваЕ. А.AseevaE. A.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow, 115522

ЗоткинЕ. Г.ZotkinE. G.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow, 115522

ШкирееваС. Ю.KireevaS. Yu.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow, 115522

НасоновЕ. Л.NasonovE. L.

115522, Москва, Каширское шоссе, 34А;

119991, Москва, ул. Трубецкая, 8, стр. 2

34A, Kashirskoe Shosse, Moscow, 115522;

8, Trubetskaya Str., Build. 2, Moscow, 119991

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian FederationФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)РоссияV.A. Nasonova Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of RussiaRussian Federation201914052019572218221Copyright © Соловьев С.К., Асеева Е.А., Зоткин Е.Г., Шкиреева С.Ю., Насонов Е.Л., 20192019Соловьев С.К., Асеева Е.А., Зоткин Е.Г., Шкиреева С.Ю., Насонов Е.Л.Soloviev S.K., Aseeva E.A., Zotkin E.G., Kireeva S.Y., Nasonov E.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/2708

За последние годы увеличилась долгосрочная выживаемость пациентов с системной красной волчанкой (СКВ) более чем до 90%, но все еще остается достаточно много нерешенных проблем. Хотя главной целью концепции «Лечение СКВ до достижения цели» является «ремиссия симптомов и отсутствие поражения органов», было признано, что общепринятого определения ремиссии при СКВ в настоящее время не существует. В статье обсуждаются различные варианты определения понятия «ремиссия» при СКВ.

In recent years, the long-term survival of patients with systemic lupus erythematosus (SLE) has increased to more than 90%, but there are still quite a few unresolved problems. Although the main objective of the concept of «Treatment of SLE to target» is «remission of symptoms and absence of organ damage», it was recognized that there is currently no generally accepted definition of remission in SLE. The article discusses different variants of the definition of «remission» in SLE.

системная красная волчанкаремиссиянизкая активностьsystemic lupus erythematosusremissionlow activityReferencesHoussiau FA, Vasconcelos C, D’Cruz D, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing lowdose and high-dose intravenous cyclophosphamide. Ann Rheum Dis. 2010;69:61-4. doi: 10.1136/ard.2008.102533Houssiau FA, Vasconcelos C, D’Cruz D, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing lowdose and high-dose intravenous cyclophosphamide. Ann Rheum Dis. 2010;69:61-4. doi: 10.1136/ard.2008.102533Bexelius C, Wachtmeister K, Skare P,et al. Drivers of cost and health-related quality of life in patients with systemic lupus erythematosus (SLE): a Swedish nationwide study based on patient reports. Lupus. 2013;22:793-801. doi: 10.1177/0961203313491849Bexelius C, Wachtmeister K, Skare P,et al. Drivers of cost and health-related quality of life in patients with systemic lupus erythematosus (SLE): a Swedish nationwide study based on patient reports. Lupus. 2013;22:793-801. doi: 10.1177/0961203313491849Eder L, Urowitz MB, Gladman DD. Damage in lupus patients – what have we learned so far? Lupus. 2013 Oct;22(12):1225-31.Eder L, Urowitz MB, Gladman DD. Damage in lupus patients – what have we learned so far? Lupus. 2013 Oct;22(12):1225-31.Rahman P, Gladman DD, Urowitz MB, et al. Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus. Lupus. 2001;10(2):93-6. doi: 10.1191/096120301670679959Rahman P, Gladman DD, Urowitz MB, et al. Early damage as measured by the SLICC/ACR damage index is a predictor of mortality in systemic lupus erythematosus. Lupus. 2001;10(2):93-6. doi: 10.1191/096120301670679959Wilhelm TR, Magder LS, Petri M. Remission in systemic lupus erythematosus: durable remission is rare. Ann Rheum Dis. 2017 Mar;76(3):547-53. doi: 10.1136/annrheumdis-2016-209489Wilhelm TR, Magder LS, Petri M. Remission in systemic lupus erythematosus: durable remission is rare. Ann Rheum Dis. 2017 Mar;76(3):547-53. doi: 10.1136/annrheumdis-2016-209489Dubois EL. Lupus Erythematosus. 2 nd ed. Los Angeles: University of Southern California Press; 1976. 243 p.Dubois EL. Lupus Erythematosus. 2 nd ed. Los Angeles: University of Southern California Press; 1976. 243 p.Van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014;73:958-67. doi: 10.1136/annrheumdis-2013-205139Van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014;73:958-67. doi: 10.1136/annrheumdis-2013-205139Steiman AJ, Urowitz MB, Ibanez D, et al. Prolonged clinical remission in patients with systemic lupus erythematosus. J Rheumatol. 2014;41:1808-16. doi: 10.3899/jrheum.131137Steiman AJ, Urowitz MB, Ibanez D, et al. Prolonged clinical remission in patients with systemic lupus erythematosus. J Rheumatol. 2014;41:1808-16. doi: 10.3899/jrheum.131137Van Vollenhoven R, Voskuyl A, Bertsias G, et al. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). Ann Rheum Dis. 2017 Mar;76(3):554-61. doi: 10.1136/annrheumdis-2016-209519. Epub 2016 Nov 24.Van Vollenhoven R, Voskuyl A, Bertsias G, et al. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). Ann Rheum Dis. 2017 Mar;76(3):554-61. doi: 10.1136/annrheumdis-2016-209519. Epub 2016 Nov 24.Franklyn K, Lau CS, Navarra SV, et al. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis. 2016 Sep;75(9):1615-21. doi: 10.1136/annrheumdis-2015-207726Franklyn K, Lau CS, Navarra SV, et al. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis. 2016 Sep;75(9):1615-21. doi: 10.1136/annrheumdis-2015-207726Heller CA, Schur PH. Serological and clinical remission in systemic lupus erythematosus. J Rheumatol. 1985 Oct;12(5):916-8.Heller CA, Schur PH. Serological and clinical remission in systemic lupus erythematosus. J Rheumatol. 1985 Oct;12(5):916-8.Drenkard C, Villa AR, Garcia-Padilla C, et al. Remission of systematic lupus erythematosus. Medicine (Baltimore). 1996;75:88-98. doi: 10.1097/00005792-199603000-00005Drenkard C, Villa AR, Garcia-Padilla C, et al. Remission of systematic lupus erythematosus. Medicine (Baltimore). 1996;75:88-98. doi: 10.1097/00005792-199603000-00005Urowitz MB, Feletar M, Bruce IN, et al. Prolonged remission in systemic lupus erythematosus. J Rheumatol. 2005 Aug;32(8):1467-72.Urowitz MB, Feletar M, Bruce IN, et al. Prolonged remission in systemic lupus erythematosus. J Rheumatol. 2005 Aug;32(8):1467-72.Medina-Quinones CV, Ramos-Merino L, Ruiz-Sada P, Isenberg D. Analysis of complete remission in systemic lupus erythematosus patients over a 32-year period. Arthritis Care Res (Hoboken). 2016 Jul;68(7):981-7. doi: 10.1002/acr.22774Medina-Quinones CV, Ramos-Merino L, Ruiz-Sada P, Isenberg D. Analysis of complete remission in systemic lupus erythematosus patients over a 32-year period. Arthritis Care Res (Hoboken). 2016 Jul;68(7):981-7. doi: 10.1002/acr.22774Zen M, Iaccarino L, Gatto M, et al. Prolonged remission in Caucasian patients with SLE: prevalence and outcomes. Ann Rheum Dis. 2015;74:2117-22. doi: 10.1136/annrheumdis-2015-207347Zen M, Iaccarino L, Gatto M, et al. Prolonged remission in Caucasian patients with SLE: prevalence and outcomes. Ann Rheum Dis. 2015;74:2117-22. doi: 10.1136/annrheumdis-2015-207347Tselios K, Gladman DD, Touma Z, et al. Clinical remission and low disease activity have comparable outcomes over 10 years in systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2018 Jul 28. doi: 10.1002/acr.23720Tselios K, Gladman DD, Touma Z, et al. Clinical remission and low disease activity have comparable outcomes over 10 years in systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2018 Jul 28. doi: 10.1002/acr.23720Aljohani R, Gladman DD, Su J, Urowitz MB. Comparison of systemic lupus erythematosus (SLE) patients managed early after diagnosis in specialty versus community care clinics. Clin Rheumatol. 2017 Aug;36(8):1773-8. doi: 10.1007/s10067-017-3713-7Aljohani R, Gladman DD, Su J, Urowitz MB. Comparison of systemic lupus erythematosus (SLE) patients managed early after diagnosis in specialty versus community care clinics. Clin Rheumatol. 2017 Aug;36(8):1773-8. doi: 10.1007/s10067-017-3713-7Mok CC, Wong RW, Lau CS. Lupus nephritis in Southern Chinese patients: clinic-pathologic findings and long-term outcome. Am J Kidney Dis. 1999;34:315-23. doi: 10.1016/S0272-6386(99)70361-6Mok CC, Wong RW, Lau CS. Lupus nephritis in Southern Chinese patients: clinic-pathologic findings and long-term outcome. Am J Kidney Dis. 1999;34:315-23. doi: 10.1016/S0272-6386(99)70361-6Illei GG, Takada K, Parkin D, et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term follow-up of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum. 2002;46:995-1002. doi: 10.1002/art.10142Illei GG, Takada K, Parkin D, et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term follow-up of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum. 2002;46:995-1002. doi: 10.1002/art.10142Lee BS, Cho HY, Kim EJ, et al. Clinical outcomes of childhood lupus nephritis: a single center’s experience. Pediatr Nephrol. 2007;22:222-31. doi: 10.1007/s00467-006-0286-0Lee BS, Cho HY, Kim EJ, et al. Clinical outcomes of childhood lupus nephritis: a single center’s experience. Pediatr Nephrol. 2007;22:222-31. doi: 10.1007/s00467-006-0286-0So MW, Koo BS, Kim YG, et al. Predictive value of remission status after 6 months induction therapy in patients with proliferative lupus nephritis: a retrospective analysis. Clin Rheumatol. 2011;30:1399-405.So MW, Koo BS, Kim YG, et al. Predictive value of remission status after 6 months induction therapy in patients with proliferative lupus nephritis: a retrospective analysis. Clin Rheumatol. 2011;30:1399-405.Fernandes das Neves M, Irlapati RV, Isenberg D. Assessment of long-term remission in lupus nephritis patients: a retrospective analysis over 30 years. Rheumatology (Oxford). 2015;54:1403-7. doi: 10.1093/rheumatology/kev003Fernandes das Neves M, Irlapati RV, Isenberg D. Assessment of long-term remission in lupus nephritis patients: a retrospective analysis over 30 years. Rheumatology (Oxford). 2015;54:1403-7. doi: 10.1093/rheumatology/kev003Carter EE, Barr SG, Clarke AE. The global burden of SLE: prevalence, health disparities and socioeconomic impact. Nat Rev Rheumatol. 2016 Oct;12(10):605-20.Carter EE, Barr SG, Clarke AE. The global burden of SLE: prevalence, health disparities and socioeconomic impact. Nat Rev Rheumatol. 2016 Oct;12(10):605-20.Ruiz-Irastorza G, Danza A, Khamashta M. Glucocorticoid use and abuse in SLE. Rheumatology (Oxford). 2012 Jul;51(7):1145-53. doi: 10.1093/rheumatology/ker410Ruiz-Irastorza G, Danza A, Khamashta M. Glucocorticoid use and abuse in SLE. Rheumatology (Oxford). 2012 Jul;51(7):1145-53. doi: 10.1093/rheumatology/ker410Iaccarino L, Andreoli L, Bartoloni Bocci L, et al. Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study. J Autoimmun. 2018;86:1-8. doi: 10.1016/j.jaut.2017.09.004Iaccarino L, Andreoli L, Bartoloni Bocci L, et al. Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study. J Autoimmun. 2018;86:1-8. doi: 10.1016/j.jaut.2017.09.004Kraaij T, Kamerling WA, de Rooij NM, et al. The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus. J Autoimmun. 2018;91:45-54. doi: 10.1016/j.jaut.2018.03.003Kraaij T, Kamerling WA, de Rooij NM, et al. The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus. J Autoimmun. 2018;91:45-54. doi: 10.1016/j.jaut.2018.03.003Bruce IN, Urowitz M, van Vollenhoven R, et al. Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care. Lupus. 2016 Jun;25(7):699-709.Bruce IN, Urowitz M, van Vollenhoven R, et al. Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care. Lupus. 2016 Jun;25(7):699-709.Doria A, Bass D, Schwarting A, et al. A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus. Lupus. 2018 Aug;27(9):1489-98. doi: 10.1177/0961203318777634Doria A, Bass D, Schwarting A, et al. A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus. Lupus. 2018 Aug;27(9):1489-98. doi: 10.1177/0961203318777634Beckwith H, Lightstone L. Rituximab in systemic lupus erythematosus and lupus nephritis. Nephron Clin Pract.2014;128(3-4):250-4. doi: 10.1159/000368585Beckwith H, Lightstone L. Rituximab in systemic lupus erythematosus and lupus nephritis. Nephron Clin Pract.2014;128(3-4):250-4. doi: 10.1159/000368585Alshaiki F, Obaid E, Almuallim A, et al. Outcomes of rituximab therapy in refractory lupus: A meta-analysis. Eur J Rheumatol. 2018 Jul;5(2):118-26. doi: 10.5152/eurjrheum.2018.17096Alshaiki F, Obaid E, Almuallim A, et al. Outcomes of rituximab therapy in refractory lupus: A meta-analysis. Eur J Rheumatol. 2018 Jul;5(2):118-26. doi: 10.5152/eurjrheum.2018.17096Gracia-Tello B, Ezeonyeji A, Isenberg D. The use of rituximab in newly diagnosed patients with systemic lupus erythematosus: longterm steroid saving capacity and clinical effectiveness. Lupus Sci Med. 2017;4:e000182. doi: 10.1136/lupus-2016-000182Gracia-Tello B, Ezeonyeji A, Isenberg D. The use of rituximab in newly diagnosed patients with systemic lupus erythematosus: longterm steroid saving capacity and clinical effectiveness. Lupus Sci Med. 2017;4:e000182. doi: 10.1136/lupus-2016-000182Меснянкина АА, Соловьев СК, Асеева ЕА, Насонов ЕЛ. Эффективность генно-инженерной биологической терапии и особенности гуморального иммунитета у больных системной красной волчанкой. Научно-практическая ревматология. 2018;56(3):302-9. doi: 10.14412/1995-4484-2018-302-309Mesnyankina AA, Solovyev SK, Aseeva EA, Nasonov EL. The efficiency of biological therapy and the features of humoral immunity in patients with systemic lupus erythematosus. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(3):302-9 (In Russ.). doi: 10.14412/1995-4484-2018-302-309

The authors declare that there are no conflicts of interest present.